Biojector®2000 Technology Used in Oman Vaccine Study

Reduced Dose of Inactivated Polio Vaccine Administered Intradermally Needle-Free

PORTLAND, Ore.--(BUSINESS WIRE)--Bioject Medical Technologies Inc. (Nasdaq:BJCT), a leading developer of needle-free drug delivery systems, today announced that the Biojector®2000 (“B2000”) needle-free system is being used in an Inactivated Polio Vaccine (“IPV”) study in Oman. The study is being conducted by the Oman Health Ministry’s Department of Communicable Disease Surveillance and Control (“DCDSC”), the World Health Organization (“WHO”) and PATH.

“We are very encouraged with results from other intradermal studies and see this as a possible delivery route for current, as well as future, vaccines. Bioject is also involved in other studies in Latin America in collaboration with the Centers for Disease Control (“CDC”

The study is intended to demonstrate whether three fractional doses of IPV given intradermally are as effective as a full dose given intramuscularly. The study will be performed with 400 newborns over a seven-month period. The Oman DCDSC is also evaluating the feasibility of using needle-free jet injectors to completely replace the needle and syringe in immunizations.

“WHO is committed to improving the safety of immunizations. The B2000 injection system is already being used to improve the safety of immunizations in numerous health centers, and WHO considers that this and other needle-free injection systems being developed by Bioject could greatly contribute to improving the safety and ease of immunizations worldwide,” said Dr. Martin Friede of WHO.

Dr. Roland Sutter of WHO stated, “Intradermal delivery of reduced doses of IPV could help countries with limited resources to use this vaccine. Intradermal delivery is difficult to perform reliably with needles and syringes, and we feel that needle-free delivery systems such as the B2000 would be a safer, easier and more reliable method for intradermal delivery of IPV.”

“We have been working with Bioject on a number of studies utilizing jet injection technology,” said Kimberly Kelly, Clinical Research Coordinator and Program Officer at PATH. “If the results of these studies are successful and dose sparing is proven, developing countries will be afforded availability of more vaccine at lower costs.”

“We are pleased to have been chosen as the needle-free delivery system for this intradermal study using IPV,” said Dr. Richard Stout, Bioject’s Executive Vice President and Chief Medical Officer. “We are very encouraged with results from other intradermal studies and see this as a possible delivery route for current, as well as future, vaccines. Bioject is also involved in other studies in Latin America in collaboration with the Centers for Disease Control (“CDC”) and WHO, which are evaluating the dose sparing possibility with other vaccines.”

Bioject Medical Technologies Inc., based in Portland, Oregon, is an innovative developer and manufacturer of needle-free drug delivery systems. Needle-free injection works by forcing medication at high speed through a tiny orifice held against the skin. This creates a fine stream of high-pressure fluid penetrating the skin and depositing medication in the tissue beneath. The Company is focused on developing mutually beneficial agreements with leading pharmaceutical, biotechnology, and veterinary companies.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such risks include that the results of clinical studies may not produce the anticipated results and that an intradermal injection device may not be commercialized or accepted. Readers of this press release are referred to the Company’s filings with the Securities and Exchange Commission, including the Company’s reports on Form 10-K and Forms 10-Q for further discussions of factors that could affect the Company’s business and its future results. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. The Company assumes no obligation to update forward-looking statements if conditions or management’s estimates or opinions should change.

For more information on Bioject, visit www.bioject.com.